PTM enzyme inhibitor - Eikonizo Therapeutics
Latest Information Update: 28 Jul 2024
At a glance
- Originator Eikonizo Therapeutics
- Class Small molecules
- Mechanism of Action Post-translational protein processing modulator
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Unspecified in USA
- 22 Jun 2020 Early research in Unspecified in USA (unspecified route) (Eikonizo Therapeutics pipeline, June 2020)